The SFN-mediated increment of ROS production has been associated with apoptotic pathway activation in various cancer types, i.e., bladder cancer, hepatocellular carcinoma, lung cancer, and breast cancer [35,36,37,38], showing a central role in preventing cancer progression. Here, SFN is linked to urinary bladder carcinoma.